Exclusive Online Content
Enlivex Announces Clinical Collaboration to Evaluate Combinations of Allocetra & PD-1 Inhibitor Tislelizumab for Patients With Solid Tumors
Enlivex Therapeutics Ltd. recently announced a clinical collaboration with BeiGene to evaluate the safety and efficacy of Allocetra, an investigational macrophage-reprogramming cell therapy, in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor, for….
A Novel Immunotherapeutic Approach to Treating Aging-Associated Diseases
HCW Biologics Inc. recently published a pivotal scientific paper in Aging Cell titled Immunotherapeutic approach to reduce senescent cells and alleviate senescence-associated secretary phenotype in mice with Dr. Hing C. Wong, the company’s Founder and CEO, as lead and….
SCYNEXIS & GSK Announce Exclusive Agreement to Commercialize & Further Develop Novel, First-in-Class Medicine to Treat Fungal Infection
SCYNEXIS, Inc. GSK plc recently announced they have entered into an exclusive license agreement for Brexafemme (ibrexafungerp tablets), a US FDA-approved, first-in-class antifungal for the….
Catalent Launches New Oral Developability Assessment & Manufacturing Solution to Advance Targeted Protein Degrader Programs
Catalent recently announced the launch of the ProteoSuite Oral suite, which allows the rational selection of orally developable targeted protein degrader (TPD) candidates and their advancement into….
Tiziana Life Sciences to Proceed With Phase 2 Clinical Trial in Patients With Non-Active Secondary Progressive Multiple Sclerosis
Tiziana Life Sciences Ltd. recently announced it has received feedback based on the US FDA Type C meeting minutes related to the Phase 2 clinical trial of intranasal foralumab in patients with non-active SPMS…..
Covant & Boehringer Ingelheim Collaborate to Develop Novel ADAR1 Inhibitor for Use in Cancer Patients
Covant Therapeutics has recently entered into an exclusive research collaboration and worldwide licensing agreement with Boehringer Ingelheim covering Covant’s ADAR1 program. The companies jointly aim….
Cyclerion Therapeutics Receives Orphan Drug Designation for the Treatment of Mitochondrial Diseases
Cyclerion Therapeutics, Inc. recently announced the US FDA has granted orphan drug designation to zagociguat (previously CY6463) for the treatment of mitochondrial diseases. Zagociguat is the first….
Jounce Therapeutics to be Acquired by Concentra Biosciences
Jounce Therapeutics, Inc. recently announced it has entered into a definitive merger agreement whereby Concentra Biosciences, LLC (Concentra) will acquire Jounce for $1.85 in cash per share plus….
Arch Biopartners Receives Funding for Development of LSALT Peptide Drug Program
Arch Biopartners Inc. recently announced it is receiving advisory services and up to $4 million in funding from the National Research Council of Canada Industrial Research Assistance Program (NRC IRAP) to support the….
Woodstock Sterile Solutions Completes Analytical Lab Expansion, Becomes One-Stop Shop CDMO
Woodstock Sterile Solutions has recently completed an expansion of its quality control analytical laboratory at its production facility in Woodstock, IL. The larger laboratory accommodates…
Stevanato Group Collaborates With Thermo Fisher Scientific to Bring its Innovative On-Body Delivery System Platform to Market
The companies will offer an integrated device and fill-and-finish solution to streamline the management of the pharmaceutical supply chain….
Vaxxinity Announces First Subjects Dosed in Phase 1 Clinical Trial of Investigational Anti-PCSK9 Vaccine to Treat Hypercholesterolemia
Vaxxinity, Inc. recently announced the first subjects have been dosed in a randomized, double-blind, placebo-controlled Phase 1 clinical trial of VXX-401, an investigational vaccine designed to lower low-density lipoprotein….
Hovione & Ripple Enter Strategic Partnership to Expand Epidel Platform Into Non-Ophthalmic Space
Hovione and Ripple Therapeutics have entered a strategic partnership to expand the use of Ripple’s Epidel® platform beyond ophthalmic applications….
Owlstone Medical Enters Partnership With Bicycle Therapeutics for the Development of Antigen-Targeted EVOC Probes for Early Cancer Detection
Owlstone Medical, the global leader in Breath Biopsy for applications in early disease detection and precision medicine, recently announced it has entered into a Research Agreement with Bicycle Therapeutics plc, a biotechnology company pioneering a new….
Pfizer Invests $43 Billion in Seagen Acquisition to Battle Cancer
Pfizer Inc. and Seagen Inc. recently announced they have entered into a definitive merger agreement under which Pfizer will acquire Seagen, a global biotechnology company that discovers, develops, and commercializes transformative cancer medicines, for $229 in cash….
Nemera & Nelson Labs Europe Strengthen Partnership to Offer Integrated Services to Customers
This strategic alliance will give a unique advantage to pharmaceutical & bio-tech customers – accelerating the go-to-market of their drug-device combination products by offering analytical chemistry, drug compatibility lab testing and expert advice….
Cingulate & Indegene Announce Joint Commercialization Agreement for Lead ADHD Candidate
Cingulate Inc. and Indegene recently announced a joint commercialization agreement to provide commercial support for Cingulate’s lead candidate CTx-1301 (dexmethylphenidate), a novel, investigational treatment….
Aenova Introduces New Sterile Strategy
Aenova Group, a leading international contract developer and manufacturer for the pharmaceutical and healthcare industries, presents its new sterile strategy…..
First Wave BioPharma Announces First Patient Dosed in Phase 2 SPAN Clinical Trial of Enhanced Adrulipase Formulation
First Wave BioPharma, Inc. recently announced that the first patient was dosed in the Phase 2 SPAN clinical trial investigating an enhanced enteric microgranule delivery formulation of….
Evonik Opens New Facility for Pharmaceutical Lipids at Site in Germany
Evonik is opening a new GMP facility to manufacture lipids for advanced, pharmaceutical drug delivery applications. The lipid launch facility is located at the company’s site in Hanau, Germany and….
